1.6 Analytical methods 1. Multiplex ligation-dependent probe amplification (MLPA). 2, 3, 5, 7, 13 2. Direct gene sequencing of ZEB-2 gene between amino acid positions 1 and 1214 (Gene Bank Accession Number NM_014795.2), by analysing exons and flanking intron sequences. 2, 3, 5, 7, 13, 14 1.7 Analytical validation (1) If a partial or complete gene deletion is detected by MLPA by several probes or by array-CGH, with reliably sufficient probes for the given array and analysis setting, no alternative validation is necessary. If the parents are analysed for mosaicism or balanced rearrangements by FISH, confirmation of FISH with molecular probes containing ZEB-2 should be performed in the index patient. If MLPA or array-CGH results are indicated by an unreliable number of probes, alternative validation should be performed by FISH, qPCR, further MLPA probes or by higher density array-CGH.
In cases with deletions, detectable by FISH, parents are investigated by FISH to look for a balanced chromosome insertion, encompassing ZEB-2 or a mosaic deletion.
If a single exon deletion is detected by a MLPA probe, the respective exon should be sequenced to exclude a mutation or polymorphism at the probe-binding site. If the latter was excluded, confirmation can be performed by real-time PCR on genomic DNA or by phenotypic analysis, in particular by facial features evaluation. 2, 3, 5, 7, 13, 14 (2) Gene mutations are validated by (a) bidirectional direct sequencing, (b) evaluation of the expected functional impairment of the altered protein and (c) exclusion of the presumed mutation in healthy parents.
1.8 Estimated frequency of the disease Estimated birth incidence is 1 in 50 000-100 000. [2] [3] [4] [5] [6] [7] 1.9 If applicable, prevalence in the ethnic group of investigated person Unknown. [2] [3] [4] [5] [6] [7] 1.10 Diagnostic setting Comment: Non-mosaic ZEB-2 mutations are fully penetrant. Parents of an affected child could be tested for a somatic mosaicism, but the detection rate is expected to be low. Healthy relatives (parents excluded) are not at risk for being mosaic for the mutation; thus, they are not eligible for the genetic test exploring a potential mosaicism. Recurrence risk in patient's siblings is about 2%, based on documented cases of gonadal mosaicism. 30, 31 Accordingly, prenatal diagnosis is offered in subsequent pregnancies of the patient's parents only. 
Will disease management be influenced by the result of a genetic test?
There is no specific treatment for MWS, as the neurological defect and also other malformations, resulting from the mutation, occur in the early stage of embryonal development. The frequent presence of serious congenital malformations require clinical investigation with intervention of neonatologists, paediatricians and several specialists. Congenital heart disease and Hirschsprung disease require early surgery during the first days or months of life. Constipation may persist after HSCR surgery. Seizures are common and require standard therapy. Genitourinary anomalies such as hypospadias, cryptorchidism, bifid scrotum, vesicoureteral reflux and hydronephrosis might be present in the first years of life and may require surgery. Eye problems are frequent and require a specialized help. Musculoskeletal anomalies, such as pes planus, calcaneovalgus deformity and scoliosis, may occur, so orthopaedic evaluation is appropriate. Audiology is recommended, although deafness is rarely present. All advised vaccinations are recommended. A periodic follow-up for the different clinical problems should be carried out regularly. Psychomotor development is retarded in all patients, and speech is almost always severely limited (typically from 0 to 100 words). Rehabilitation, including physical therapy, psychomotor and speech therapy, should be started as soon as possible. Augmented communication (signing, picture exchange, Makaton) is recommended. 
IF APPLICABLE, FURTHER CONSEQUENCES OF TESTING
A positive genetic test is greatly useful for family members. It restricts a low recurrence risk to subsequent siblings of the diseased person. On the contrary, each healthy family member has not an increased risk of having affected children, with the only exclusion of the healthy parents of the affected person because of a possible gonadal or somatic mosaicism.
